Text Size

Cranberry for UTI Prevention in Residents of Long Term Care Facilities (PACS)

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Yale University
ClinicalTrials.gov Identifier:
NCT00596635
First received: January 8, 2008
Last updated: March 19, 2013
Last verified: March 2013
History of Changes
Results First Received: June 30, 2010  
Study Type: Interventional
Study Design: Allocation: Randomized;   Intervention Model: Single Group Assignment;   Masking: Open Label;   Primary Purpose: Prevention
Condition: Urinary Tract Infection
Interventions: Dietary Supplement: Once Daily Cranberry Capsule
Dietary Supplement: Twice Daily Cranberry Capsules

  Participant Flow
  Hide Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
Four dementia units participated in this study. Exclusion criteria included: 1)indwelling catheter, 2)residence <4 weeks, 3)prednisone therapy, 4)active UTI symptoms, 5)terminal, 6)end stage renal disease, 7)<60 years old, 8)chronic suppressive antibiotic therapy, 9)history of kidney stones, 10)unable to provide baseline urine, 11)warfarin therapy.

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
If a participant could not provide a baseline urine specimen or met an exclusion criterion prior to group assignment but after consent, he or she was not enrolled.

Reporting Groups
  Description
No Cranberry Capsules Control Group No Cranberry Capsule
One Cranberry Capsule 1 650mg cranberry capsule daily
2 Cranberry Capsules 1 650 mg cranberry capsule twice daily (bid)

Participant Flow:   Overall Study
    No Cranberry Capsules     One Cranberry Capsule     2 Cranberry Capsules  
STARTED     17     20     19  
COMPLETED     10     7     11  
NOT COMPLETED     7     13     8  
Lost to Follow-up                 0                 2                 0  
Treatment for symptomatic UTI                 4                 6                 3  
Hip fracture                 2                 3                 3  
Could not provide urine specimen                 1                 2                 2  



  Baseline Characteristics
  Hide Baseline Characteristics

Reporting Groups
  Description
No Cranberry Capsules Control Group No Cranberry Capsule
One Cranberry Capsule 1 650mg cranberry capsule daily
2 Cranberry Capsules 1 650 mg cranberry capsule twice daily (bid)
Total Total of all reporting groups

Baseline Measures
    No Cranberry Capsules     One Cranberry Capsule     2 Cranberry Capsules     Total  
Number of Participants  
[units: participants]
 		  17     20     19     56  
Age  
[units: participants]
 		       
<=18 years     0     0     0     0  
Between 18 and 65 years     1     0     0     1  
>=65 years     16     20     19     55  
Age  
[units: years]
Mean ± Standard Deviation 		  85.76  ± 11.76     88.30  ± 6.16     86.68  ± 5.16     86.82  ± 7.97  
Gender  
[units: participants]
 		       
Female     13     17     16     46  
Male     4     3     3     10  
Region of Enrollment  
[units: participants]
 		       
United States     17     20     19     56  



  Outcome Measures
  Show All Outcome Measures

1.  Primary:   Number of Urine Cultures Collected Out of the Total Number Expected to be Collected.   [ Time Frame: 6 months ]
  Show Outcome Measure 1

2.  Secondary:   Number of Participants With E.Coli Isolated From Urine Culture   [ Time Frame: 6 months ]
  Show Outcome Measure 2

3.  Secondary:   Number of Participants With >100,000 Colony Forming Units Per Milliliter of Any Organism Isolated From Urine Culture   [ Time Frame: 6 months ]
  Show Outcome Measure 3


  Serious Adverse Events
  Show Serious Adverse Events


  Other Adverse Events
  Show Other Adverse Events


  More Information
  Hide More Information

Certain Agreements:  
All Principal Investigators ARE employed by the organization sponsoring the study.


Limitations and Caveats
Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
The inability to follow all participants for the full six months reflects the vulnerability of the population.  


Results Point of Contact:  
Name/Title: Manisha Juthani-Mehta, MD
Organization: Yale University School of Medicine
phone: (203)785-4140
e-mail: manisha.juthanimehta@yale.edu


Publications of Results:


Responsible Party: Yale University
ClinicalTrials.gov Identifier: NCT00596635     History of Changes
Other Study ID Numbers: 0606001581, DF06-005
Study First Received: January 8, 2008
Results First Received: June 30, 2010
Last Updated: March 19, 2013
Health Authority: United States: Institutional Review Board